Market Predictions for 2026: Potential Winners
The future of the stock market in 2026 is quite uncertain. While there’s a chance it could keep climbing, we might also see a slowdown of last year’s strong performance.
Still, I have a feeling that individual stocks might actually do better. This year will be quite pivotal for the S&P 500, and I’d like to highlight three specific stocks that I believe could really outshine the competition by 2026.
There’s some buzz around the idea that AI could set the stage for the first million-dollar earners. Recently, a report highlighted a lesser-known company described as an “essential monopoly,” pivotal in supplying technology crucial to giants like Nvidia and Intel.
Let’s not forget about Alphabet, the parent company of Google. Even with some recent declines, it has shown considerable gains over the last year. Personally, I really hope this positive trend persists, especially within the artificial intelligence sector.
In its last quarterly update, Alphabet hinted at a bright future. The CFO noted that Google Cloud’s backlog jumped 55% from the previous quarter, more than doubling from the year before—now at $240 billion. This suggests that its revenue could surge as Google Cloud starts converting this backlog into earnings throughout 2026.
To give you some context, Google Cloud’s annual revenue at the end of 2025 was around $70 billion. It’s quite clear why there’s so much growth in its backlog; customers are increasingly turning to Google Cloud for its enterprise AI offerings, particularly those based on the robust Gemini 3.0 model.
There’s also a lot of excitement around Agentic AI. Its platform, Google Antigravity, leverages AI agents for complex tasks and has quickly gained popularity among developers. Plus, Google is integrating AI into its Chrome browser and enhancing its advertising tools, which leads me to believe that these investments will likely yield positive results soon.
Switching gears to biotech, I think stocks like B-One Medicine could provide notable returns, especially considering it usually delivers solid catalysts within a year. By 2026, it might have three potential catalysts brewing.
B-One, formerly known as BeiGene, has a successful drug called Burkinsa for blood cancer that is capturing market share from Imbruvica and is now the leading BTK inhibitor. The company plans to release results this year from a Phase 3 study exploring Burkinsa with rituximab for treating mantle cell lymphoma.
While I expect Burkinsa to maintain its positive momentum, it might not be the most significant news for B-One. That distinction could go to Sonlotoclax, as the company aims to secure US regulatory approval for this treatment in the first half of the year.
Moreover, B-One may apply for accelerated approval for another drug, BGB-16673, targeting chronic lymphocytic leukemia later this year, depending on favorable Phase 2 trial results.
Another promising biotech stock is Rhythm Pharmaceuticals. They currently have a single product, Imcivree, approved for genetic obesity disorders but might soon expand their product lineup. The FDA is set to decide on the approval of Imsivly for treating acquired hypothalamic obesity by March 20, 2026. This approval could significantly boost Rhythm’s stock value since this condition affects more patients than those covered by currently approved indications combined.
Investors have more to anticipate, as Rhythm plans to report Phase 3 trial data for Imsivly across additional genetic diseases in early 2026 and will share interim results for a treatment exploring Prader-Willi syndrome. Although this syndrome is not common, it touches around 400,000 individuals globally, presenting a potentially lucrative market for Rhythm.
Before pulling the trigger on buying Alphabet stock, keep this in mind: the analysts at Motley Fool Stock Advisor have pointed out ten stocks they believe could outperform significantly over the next several years, and Alphabet isn’t on that list. A bit of a surprising twist, really.
In summary, while the stock market’s future remains unpredictable, some individual stocks, particularly in the tech and biotech sectors, seem poised for notable success in 2026.
